 "new and different"; and, to an economist, "expensive." 
flood of new antipsychotics is generating improved treatments for schizophrenia but tangled terminology for clinicians. All of the newer antipsychotics since clozapine have been lumped into a new therapeutic class often referred to as "atypical" [1] [2] [3] [4] ( Table 1 ). This includes not only risperidone, olanzapine, and quetiapine, but also sertindole (marketed only outside the United States) and ziprasidone (expected to be approved in the United States soon). Lumping all of the new agents together helps to distinguish them as a class from most of the older conventional antipsychotics, which are clearly less tolerated and possibly less effective, especially for negative symptoms. [1] [2] [3] [4] [5] These new agents must distinguish themselves from the older generic agents if they hope to support price premiums.
However, by considering all of the new drugs as one class, differences among newer drugs are obscured. Thus, there are also attempts to distinguish 1 new agent from another. So far, the results are intriguing, even controversial. [6] [7] [8] It is already clear from anecdotal use-if not yet from controlled clinical trials-that individual patients can show dramatic differences in efficacy as well as tolerability from 1 of the newer agents to another. Furthermore, as new standards in pharmacology and clinical evaluations are applied to the older agents, some surprising findings among those agents are beginning to emerge ( Table 2) . 9 All new and old antipsychotics improve positive symptoms and are also D 2 receptor antagonists. 4 All new antipsychotics block 5-HT 2A receptors as well and have fewer extrapyramidal side effects (EPS) at low doses than the conventional antipsychotics have at standard doses. [1] [2] [3] [4] [5] [6] [7] [8] [9] One atypical antipsychotic (quetiapine) has no more EPS than placebo. 8 So far, at least 2 antipsychotics (olanzapine and risperidone) have shown greater efficacy than a conventional antipsychotic for negative symptoms, and 2 (olanzapine and quetiapine) do not raise prolactin like the conventional drugs do. [6] [7] [8] Early indications are that ziprasidone may cause less weight gain compared with all other new and old agents. [1] [2] [3] How many, if any, of the "atypical" properties are due to 5-HT 2 antagonism remains a quandary, although it is a good bet that it is this A Take-Home Points x There are multiple definitions for an atypical antipsychotic.
x The "atypical" concept is dependent upon dose: less is more.
x Some atypicals may be more atypical than others.
x Even some conventional antipsychotics may be atypical. 6 , and 5-HT 7 receptors; to α 1 , α 2 , H 1 , and muscarinic cholinergic receptors; and to serotonin and norepinephrine reuptake pumps. [1] [2] [3] [4] [5] [6] [7] [8] [9] It is well known that many of the old antipsychotics bind α 1 , muscarinic, and histamine receptors in addition to D 2 receptors 4 ; however, what is not so well known is that a few traditional antipsychotics also bind to the 5-HT 2A receptor just like the new antipsychotics. 9 These include loxapine as well as chlorpromazine and thioridazine. 9, 11 Positron emission tomography studies of loxapine in schizophrenic patients confirm its significant 5-HT 2 binding properties, but chlorpromazine does not seem to bind to 5-HT 2 receptors except at high doses. 9, 11 Thus, is loxapine the "Cinderella" antipsychotic waiting to be invited to the low-dose atypical antipsychotic ball? Given these provocative data plus the current lack of availability of an intramuscular dosage formulation for any new antipsychotic, another look at this less expensive agent, both orally and in its available parenteral form, appears to be in order.
Research on the antipsychotics is proceeding at a fast and furious pace; some of these preliminary distinctions among agents may be lost and yet others proved. No matter what we end up calling the new antipsychotics, it is clear that they represent a significant advance in therapeutics for schizophrenia. x 
